Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROMPT: ProHema-CB in pediatric hematologic malignancies
NCT02354417Phase 1Terminated
- Sponsor
- Fate Therapeutics
- Start
- Dec 2014
- Primary completion
- Dec 2016
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of ProHema in hematologic malignancy, sponsored by Fate Therapeutics. Primary endpoint: Safety Profile, Primarily Assessed by Neutrophil Engraftment at Day 42. Started Dec 2014; status: terminated.
02
Drugs
ProHema
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT02354417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02354417.